BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 25269391)

  • 21. Safety and efficacy of prophylaxis for Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation.
    Prasad GVR; Beckley J; Mathur M; Gunasekaran M; Nash MM; Rapi L; Huang M; Zaltzman JS
    BMC Infect Dis; 2019 Apr; 19(1):311. PubMed ID: 30953458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interventions for the prevention of recurrent erysipelas and cellulitis.
    Dalal A; Eskin-Schwartz M; Mimouni D; Ray S; Days W; Hodak E; Leibovici L; Paul M
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009758. PubMed ID: 28631307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pneumocystis pneumonia in patients with immunosuppression other than HIV infection].
    Adler D; Chenivesse C; Similowski T; Soccal PM
    Rev Med Suisse; 2008 Nov; 4(180):2525-6, 2528-30. PubMed ID: 19127897
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term antibiotics for preventing recurrent urinary tract infection in children.
    Williams G; Craig JC
    Cochrane Database Syst Rev; 2019 Apr; 4(4):CD001534. PubMed ID: 30932167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticosteroids for pneumonia.
    Stern A; Skalsky K; Avni T; Carrara E; Leibovici L; Paul M
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD007720. PubMed ID: 29236286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.
    Goldenberg JZ; Yap C; Lytvyn L; Lo CK; Beardsley J; Mertz D; Johnston BC
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD006095. PubMed ID: 29257353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
    Salzer HJF; Schäfer G; Hoenigl M; Günther G; Hoffmann C; Kalsdorf B; Alanio A; Lange C
    Respiration; 2018; 96(1):52-65. PubMed ID: 29635251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study.
    Yamashita K; Shimomura Y; Ikesue H; Muroi N; Yoshimoto A; Hashida T
    BMC Infect Dis; 2021 Jul; 21(1):664. PubMed ID: 34238239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interventions for primary vesicoureteric reflux.
    Williams G; Hodson EM; Craig JC
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD001532. PubMed ID: 30784039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia resolution in people with cancer.
    Stern A; Carrara E; Bitterman R; Yahav D; Leibovici L; Paul M
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012184. PubMed ID: 30605229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conventional-dose Versus Half-dose Sulfamethoxazole-trimethoprim for the Prophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Disease: A Non-blind, Randomized Controlled Trial.
    Abe Y; Fujibayashi K; Nishizaki Y; Yanagisawa N; Nojiri S; Nakano S; Tada K; Yamaji K; Tamura N
    Acta Med Okayama; 2019 Feb; 73(1):85-89. PubMed ID: 30820060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotic therapy for pelvic inflammatory disease.
    Savaris RF; Fuhrich DG; Duarte RV; Franik S; Ross J
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010285. PubMed ID: 28436019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isoniazid for preventing tuberculosis in HIV-infected children.
    Zunza M; Gray DM; Young T; Cotton M; Zar HJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD006418. PubMed ID: 28850172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: A systematic review and meta-analysis.
    Li R; Tang Z; Liu F; Yang M
    PLoS One; 2021; 16(3):e0248524. PubMed ID: 33765022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of a primary prophylaxis strategy.
    Chokephaibulkit K; Wanachiwanawin D; Chearskul S; Wanprapa N; Unganont K; Tantinikorn W; Udompunthurak S
    Pediatr Infect Dis J; 1999 Feb; 18(2):147-52. PubMed ID: 10048687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.
    Sharma SK; Sharma A; Kadhiravan T; Tharyan P
    Evid Based Child Health; 2014 Mar; 9(1):169-294. PubMed ID: 25404581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylaxis for Pneumocystis pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study.
    Katsuyama T; Saito K; Kubo S; Nawata M; Tanaka Y
    Arthritis Res Ther; 2014 Feb; 16(1):R43. PubMed ID: 24495443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure.
    Siu JT; Nguyen T; Turgeon RD
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD012123. PubMed ID: 33294991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study.
    Otani T; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Hirata S; Fujitaka K; Hamada H; Sugiyama E; Hattori N
    Pulm Pharmacol Ther; 2021 Apr; 67():101999. PubMed ID: 33571651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.